The journal of allergy and clinical immunology. In practice · 2025
Comparison of Three Treatment Strategies in Mild Asthma: A Carbon-Utility Analysis.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vieira Rafael José, Duarte Vítor Henrique, Bognanni Antonio, Gil-Mata Sara, Marques-Cruz Manuel, Pereira Ana Margarida, Chen-Xu José, Louis Renaud, Williams Sian, Nadeau Kari C, Haahtela Tari, Piggott Thomas, Fonseca João A, Antó Josep M, Schünemann Holger J, Bousquet Jean, Sousa-Pinto Bernardo
Аннотация
BACKGROUND: The main types of commercially available inhalers for the management of asthma include dry powder inhalers (DPIs) and pressurized metered-dose inhalers (pMDIs). The environmental impact of pMDIs, due to hydrofluorocarbon propellants, is a growing concern.
OBJECTIVE: To conduct a carbon-utility analysis in mild asthma, comparing the clinical efficacy of DPIs versus pMDIs alongside their associated environmental impacts.
METHODS: We performed a carbon-utility analysis using data from the Novel START trial, comparing 3 treatment strategies for mild asthma: as-needed budesonide/formoterol DPI, as-needed salbutamol pMDI, and maintenance budesonide DPI plus as-needed salbutamol pMDI. We calculated carbon dioxide equivalent (kgCO2e) emissions per quality-adjusted life year (QALY) gained. Results were compared to predefined willingness-to-emit thresholds based on health care CO2e emissions in the United States, the European Union, and the United Kingdom.
RESULTS: As-needed budesonide/formoterol DPI had a yearly carbon footprint of 1.1 kgCO2e and a utility of 0.936, compared with 26.2 kgCO2e and 0.935 for as-needed salbutamol pMDI, and 17.3 kgCO2e and 0.944 for maintenance budesonide DPI plus as-needed salbutamol pMDI. Compared with budesonide/formoterol, budesonide plus salbutamol resulted in 2192 more kgCO2e per QALY gained, exceeding the US per capita kgCO2e emissions in the health care sector and its 2030 target values. As-needed salbutamol was associated with higher CO2e emissions and lower utilities than budesonide/formoterol.
CONCLUSION: We applied to the asthma field a novel methodological approach to consider both the environmental impact and effectiveness of interventions. These findings indicate that as-needed budesonide/formoterol DPI is the preferred option when considering both carbon emissions and treatment effectiveness.
OBJECTIVE: To conduct a carbon-utility analysis in mild asthma, comparing the clinical efficacy of DPIs versus pMDIs alongside their associated environmental impacts.
METHODS: We performed a carbon-utility analysis using data from the Novel START trial, comparing 3 treatment strategies for mild asthma: as-needed budesonide/formoterol DPI, as-needed salbutamol pMDI, and maintenance budesonide DPI plus as-needed salbutamol pMDI. We calculated carbon dioxide equivalent (kgCO2e) emissions per quality-adjusted life year (QALY) gained. Results were compared to predefined willingness-to-emit thresholds based on health care CO2e emissions in the United States, the European Union, and the United Kingdom.
RESULTS: As-needed budesonide/formoterol DPI had a yearly carbon footprint of 1.1 kgCO2e and a utility of 0.936, compared with 26.2 kgCO2e and 0.935 for as-needed salbutamol pMDI, and 17.3 kgCO2e and 0.944 for maintenance budesonide DPI plus as-needed salbutamol pMDI. Compared with budesonide/formoterol, budesonide plus salbutamol resulted in 2192 more kgCO2e per QALY gained, exceeding the US per capita kgCO2e emissions in the health care sector and its 2030 target values. As-needed salbutamol was associated with higher CO2e emissions and lower utilities than budesonide/formoterol.
CONCLUSION: We applied to the asthma field a novel methodological approach to consider both the environmental impact and effectiveness of interventions. These findings indicate that as-needed budesonide/formoterol DPI is the preferred option when considering both carbon emissions and treatment effectiveness.